Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome + rituximab + lenalidomide
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Mitoxantrone hydrochloride liposome + rituximab + lenalidomide is an investigational chemo-immunotherapy combination regimen being evaluated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The regimen includes **mitoxantrone hydrochloride liposome** (Duoenda), a nanoparticle-encapsulated anthracenedione that intercalates into DNA and inhibits topoisomerase II while reducing cardiotoxicity compared to conventional mitoxantrone. **Rituximab** is a chimeric monoclonal antibody that targets the CD20 antigen on B-lymphocytes, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. **Lenalidomide** is an oral immunomodulatory drug (IMiD) that binds to the cereblon E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos, which results in direct antineoplastic effects and enhancement of T-cell and NK-cell mediated immunity. This triplet combination is currently being studied in Phase 2 clinical trials led by Jianfeng Zhou at Tongji Hospital to improve outcomes in patients with aggressive B-cell malignancies.
- Brand names
- Duoenda
- Other names
- R-MLR-LMMitoxantrone Liposome + Rituximab + Lenalidomide
02
Targets
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome + rituximab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome + rituximab + lenalidomide.